The talk of the show?

23 Oct 2019

Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPhI WW.

Ahead of CPhI Worldwide in Frankfurt next week, Barbara Morgan, Pharmaceutical Business Director at Lubrizol Life Science Health discusses the trends she expects to be the talk of the show.

The talk of the show?

What do you think will be the major trends and talking points at CPhI Worldwide 2019?

We expect to see a continuation of the growing trend of outsourcing the full spectrum of pharmaceutical services, including commercial manufacturing. Recent figures show that only around one third of manufacturing — whether in the development stages or after commercial launch — is conducted in-house. This year, we have invested in our own commercial manufacturing capabilities with the opening of a new commercial manufacturing facility which is now up and running and recently produced its first set of three registration batches.

The ongoing growth of the biologics market over the past few years will likely be reflected on the show floor, particularly as 2019 has witnessed the FDA releasing guidelines on how biosimilars can achieve an interchangeable status and substitute the reference biologic without a prescriber intervening.

There has also been much discussion this year about the pricing pressures on generics, with regulators, patients and politicians seeking to drive down prices.

In terms of drug development trends, we expect to see an increased focus on long-acting products such as microparticle depots and implants as drug developers seek dosage forms that can aid better patient compliance. This is a topic we are keen to discuss with visitors to our stand.

What is your company hoping to achieve at this year's event?

This year we’re hoping to engage in discussions that center around GMP for clinical trial supply and commercial manufacturing. Lubrizol Life Science Health is currently well known for its focus on complex drug development projects. We’re keen to expand our client base and engage with those who are not yet familiar with our unique capabilities around commercial manufacturing of small batch size products.

What do you most look forward to about CPhI?

I enjoy how well-organized and efficient the CPhI Worldwide event is and the fact that it brings so many people in the industry together, giving you an opportunity to catch up with those clients that you don’t often see in person. It also provides a great environment for meeting new clients and prospects and learning more about the latest trends and talking points in the industry among like-minded peers.

Any presentations/events or news you'd like to tell us about?

This year our big announcement is that we will be changing our name from Particle Sciences to Lubrizol Life Science Health. The name change is an outward sign of our official transition under the Lubrizol Life Science brand umbrella.

As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation, providing customers with greater support and market insights that help them meet their goals.

Related news

Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies

8 Nov 2019

But personalized medicines will require new logistics and manufacturing systems.

Read more 
Europe predicted to surpass the US in biologic manufacturing capacity by 2023

Europe predicted to surpass the US in biologic manufacturing capacity by 2023

6 Nov 2019

Demand for biological manufacturing is growing faster than capacity growth.

Read more 
China on course for 'massive' bio capacity shortfall

China on course for 'massive' bio capacity shortfall

4 Nov 2019

A shortage of qualified personnel may be a drag factor in cell and gene therapies; in China 100,00L of capacity will need to be added every year to meet bio demand.

Read more 
German pharma benefiting from a Brexit boost?

German pharma benefiting from a Brexit boost?

24 Oct 2019

Germany establishes itself as Europe's leading pharma market in 2019.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Cytel to hold Complex Innovative Trial Design Symposium

Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Read more 
Finalists announced for this year's CPhI Worldwide Awards

Finalists announced for this year's CPhI Worldwide Awards

17 Oct 2019

The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
Industry on the brink of a new age of smart pharma manufacturing

Industry on the brink of a new age of smart pharma manufacturing

27 Sep 2019

Report predicts tomorrow’s biggest industry winners will need to invest now ahead of the curve.

Read more